HighMark Wealth Management LLC Has $178,000 Stake in Solventum Corporation $SOLV

HighMark Wealth Management LLC raised its position in shares of Solventum Corporation (NYSE:SOLV) by 8.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,349 shares of the company’s stock after acquiring an additional 188 shares during the period. HighMark Wealth Management LLC’s holdings in Solventum were worth $178,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Chelsea Counsel Co. lifted its position in shares of Solventum by 720.7% during the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after purchasing an additional 9,304 shares during the last quarter. ST Germain D J Co. Inc. lifted its holdings in shares of Solventum by 84.6% during the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock worth $63,000 after buying an additional 378 shares during the last quarter. CX Institutional lifted its holdings in shares of Solventum by 11.7% during the second quarter. CX Institutional now owns 2,376 shares of the company’s stock worth $180,000 after buying an additional 249 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in shares of Solventum in the second quarter valued at approximately $71,000. Finally, Public Employees Retirement System of Ohio grew its stake in shares of Solventum by 0.9% in the second quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock worth $4,832,000 after acquiring an additional 583 shares during the last quarter.

Solventum Trading Up 2.1%

Shares of SOLV opened at $74.56 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock has a market cap of $12.93 billion, a PE ratio of 34.52, a PEG ratio of 2.97 and a beta of 0.50. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The stock has a 50 day simple moving average of $72.82 and a 200-day simple moving average of $72.22.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SOLV. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Tuesday, July 1st. Wall Street Zen downgraded shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. KeyCorp started coverage on shares of Solventum in a research report on Friday, June 6th. They set a “sector weight” rating for the company. Jefferies Financial Group began coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target for the company. Finally, Piper Sandler reiterated an “overweight” rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $84.60.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.